ERBB2 and breast cancer: Subgroup analyses proves that MTDH is implicated in trastuzumab resistance in HER2 positive breast cancer, which is further confirmed by elevated MTDH but reduced PTEN expressions in trastuzumab-resistant breast cancer cells.